Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Aerie Pharmaceuticals patents

Patents where

Current Assignee

Name

Aerie Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11618748 Dual mechanism inhibitors for the treatment of disease	Patent 11618748 was granted and assigned to Aerie Pharmaceuticals on April, 2023 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11618748	April 4, 2023
‌ US Patent 10112920 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 10112920 was granted and assigned to Aerie Pharmaceuticals on October, 2018 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	10112920	October 30, 2018
‌ US Patent 10174017 Dual mechanism inhibitors for the treatment of disease	Patent 10174017 was granted and assigned to Aerie Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	10174017	January 8, 2019
‌ US Patent 10882840 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 10882840 was granted and assigned to Aerie Pharmaceuticals on January, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	10882840	January 5, 2021
‌ US Patent 11312700 Aryl cyclopropyl-amino-isoquinolinyl amide compounds	Patent 11312700 was granted and assigned to Aerie Pharmaceuticals on April, 2022 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11312700	April 26, 2022
‌ US Patent 11590123 Ophthalmic compositions		Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11590123	February 28, 2023
‌ US Patent 10532993 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 10532993 was granted and assigned to Aerie Pharmaceuticals on January, 2020 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	10532993	January 14, 2020
‌ US Patent 11021456 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 11021456 was granted and assigned to Aerie Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11021456	June 1, 2021
‌ US Patent 9512101 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 9512101 was granted and assigned to Aerie Pharmaceuticals on December, 2016 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	9512101	December 6, 2016
‌ US Patent 7470787 Isoquinoline compounds	Patent 7470787 was granted and assigned to Aerie Pharmaceuticals on December, 2008 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	7470787	December 30, 2008
‌ US Patent 11028081 Dual mechanism inhibitors for the treatment of disease	Patent 11028081 was granted and assigned to Aerie Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11028081	June 8, 2021
‌ US Patent 11427563 Aryl cyclopropyl-amino-isoquinolinyl amide compounds	Patent 11427563 was granted and assigned to Aerie Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11427563	August 30, 2022
‌ US Patent 9096569 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 9096569 was granted and assigned to Aerie Pharmaceuticals on August, 2015 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	9096569	August 4, 2015
‌ US Patent 8450344 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Patent 8450344 was granted and assigned to Aerie Pharmaceuticals on May, 2013 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	8450344	May 28, 2013
‌ US Patent 10899714 6-aminoisoquinoline compounds	Patent 10899714 was granted and assigned to Aerie Pharmaceuticals on January, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	10899714	January 26, 2021
‌ US Patent 11020385 Combination therapy	Patent 11020385 was granted and assigned to Aerie Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11020385	June 1, 2021
‌ US Patent 11389441 Ophthalmic compositions	Patent 11389441 was granted and assigned to Aerie Pharmaceuticals on July, 2022 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11389441	July 19, 2022
‌ US Patent 10568878 Combination therapy	Patent 10568878 was granted and assigned to Aerie Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	10568878	February 25, 2020
‌ US Patent 9963432 Beta-amino-isoquinolinyl amide compounds	Patent 9963432 was granted and assigned to Aerie Pharmaceuticals on May, 2018 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	9963432	May 8, 2018
‌ US Patent 11185538 Compositions for treating glaucoma or reducing intraocular pressure	Patent 11185538 was granted and assigned to Aerie Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11185538	November 30, 2021
‌ US Patent 10316029 Dual mechanism inhibitors for the treatment of disease	Patent 10316029 was granted and assigned to Aerie Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	10316029	June 11, 2019
‌ US Patent 8394826 Dual mechanism inhibitors for the treatment of disease	Patent 8394826 was granted and assigned to Aerie Pharmaceuticals on March, 2013 by the United States Patent and Trademark Office.		Aerie Pharmaceuticals	United States Patent and Trademark Office	8394826	March 12, 2013
‌ US Patent 9951059 Dual mechanism inhibitors for the treatment of disease	Patent 9951059 was granted and assigned to Aerie Pharmaceuticals on April, 2018 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	9951059	April 24, 2018
‌ US Patent 9415043 Combination therapy	Patent 9415043 was granted and assigned to Aerie Pharmaceuticals on August, 2016 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	9415043	August 16, 2016
‌ US Patent 11197853 Combination therapy	Patent 11197853 was granted and assigned to Aerie Pharmaceuticals on December, 2021 by the United States Patent and Trademark Office.	Aerie Pharmaceuticals	Aerie Pharmaceuticals	United States Patent and Trademark Office	11197853	December 14, 2021

Results per page:

57 results

0 selected

57 results

0 selected